Pfizer and BioNTech have announced that a large-scale trial of their Corona Vaccine Booster has shown that it restores complete protection against the disease.
According to the report of the news agency Xinhua, in the third phase controlled trial, more than 10,000 people aged 16 years and above were given a booster dose of Pfizer-BioNTech against Kovid, who had previously been given its primary two doses.
It showed 95.6 percent efficiencies compared to those who did not receive the booster.
These are the first AFIKC results of any controlled corona vaccine booster trial.
“These results provide further evidence of the benefits of boosters as we aim to keep people well-protected from this disease,” said Albert Boerla, Pfizer’s President and CEO.
Last month i.e. in September this year, the US Food and Drug Administration approved the booster shots of Pfizer-BioNTech’s Covid-19.
In addition, the FDA has recently authorized COVID-19 booster doses from Moderna and Johnson & Johnson and has also approved a ‘mix and match’ for booster dose with the current approved corona vaccine. Is.
In the US, a booster dose of the corona vaccine has been approved for people over the age of 65, except for those who are at high risk of exposure to SARS-CoV-2.
In case of two primary dose corona vaccine, the booster dose can be taken at least 6 months after the primary dose. Whereas in the case of single-dose Johnson & Johnson’s corona vaccine, the FDA has authorized the use of a booster dose at least 2 months after the completion of the single dose.